» Articles » PMID: 33224875

Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Nov 23
PMID 33224875
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Endometrial cancer is the most common malignancy of the female genital tract and its incidence is rising in parallel with the mounting prevalence of obesity. Early diagnosis has great potential to improve outcomes as treatment can be curative, especially for early stage disease. Current tests and procedures for diagnosis are limited by insufficient accuracy in some and unacceptable levels of invasiveness and discomfort in others. There has, therefore, been a growing interest in the search for sensitive and specific biomarkers for endometrial cancer detection based on non-invasive sampling methodologies. Urine, the prototype non-invasive sample, is attractive for biomarker discovery as it is easily accessible and can be collected repeatedly and in quantity. Identification of urinary biomarkers for endometrial cancer detection relies on the excretion of systemic biomarkers by the kidneys or urinary contamination by biomarkers shed from the uterus. In this review, we present the current standing of the search for endometrial cancer urinary biomarkers based on cytology, genomic, transcriptomic, proteomic, and metabolomic platforms. We summarize the biomarker candidates and highlight the challenges inherent in urinary biomarker discovery. We review the various technologies with promise for biomarker detection and assess these novel approaches for endometrial cancer biomarker research.

Citing Articles

Non-Invasive Detection of Tumors by Volatile Organic Compounds in Urine.

Hara T, Meng S, Arao Y, Saito Y, Inoue K, Alshammari A Biomedicines. 2025; 13(1).

PMID: 39857693 PMC: 11762175. DOI: 10.3390/biomedicines13010109.


Gynecological Insights into Lynch Syndrome-A Comprehensive Review of Cancer Screening and Prevention.

Chitoran E, Bohiltea R, Rotaru V, Durdu C, Mitroiu M, Simion L Medicina (Kaunas). 2025; 60(12.

PMID: 39768893 PMC: 11728026. DOI: 10.3390/medicina60122013.


A Multi-Channel Urine Sensing Detection System Based on Creatinine, Uric Acid, and pH.

Gao Q, Fu J, Xiong F, Wang J, Qin Z, Li S Biosensors (Basel). 2024; 14(10).

PMID: 39451686 PMC: 11506577. DOI: 10.3390/bios14100473.


Non-Invasive Endometrial Cancer Screening through Urinary Fluorescent Metabolome Profile Monitoring and Machine Learning Algorithms.

Svecova M, Dubayova K, Birkova A, Urdzik P, Marekova M Cancers (Basel). 2024; 16(18).

PMID: 39335127 PMC: 11429905. DOI: 10.3390/cancers16183155.


Plasma-based proteomic profiling identifies the distinct regulation of proteins in hyperplasia and endometrial cancer.

Akkour K, Alanazi I, Alfadda A, Masood A, Alhalal H, Joy S BMC Cancer. 2024; 24(1):752.

PMID: 38902713 PMC: 11191338. DOI: 10.1186/s12885-024-12522-0.


References
1.
Bufa A, Biro I, Poor V, Molnar G, Kovacs K, Felinger A . Altered urinary profiles of endogenous steroids in postmenopausal women with adenocarcinoma endometrii. Gynecol Endocrinol. 2009; 26(1):10-5. DOI: 10.3109/09513590903159581. View

2.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

3.
Liang S, Fu L . Application of single-cell technology in cancer research. Biotechnol Adv. 2017; 35(4):443-449. DOI: 10.1016/j.biotechadv.2017.04.001. View

4.
Burke W . Genetic tests: clinical validity and clinical utility. Curr Protoc Hum Genet. 2014; 81:9.15.1-9.15.8. PMC: 4084965. DOI: 10.1002/0471142905.hg0915s81. View

5.
Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9):1067-1074. PMC: 6219495. DOI: 10.1038/s41416-018-0310-8. View